The goal of our lab

What we do in the lab

Our Research

Neurodegenerative diseases, including Alzheimer’s (AD), Parkinson’s (PD), and Amyotrophic Lateral Sclerosis (ALS), impact over a billion people globally, a number expected to rise due to the lack of effective treatments and the aging population. Recent human genetic advances have identified numerous genes linked to neurodegeneration. These findings are key for finding effective treatments because drug targets with genetic support have a bigger chance of success in clinical trials. My Lab leverages computational strategies to translate genetic data from neurodegenerative diseases into drug discovery.

Signature reversion principle in drug identification

Our objective

The primary objective of our Lab is to employ the signature reversion principle in drug identification. This is a data-driven strategy that compares drug-induced gene expression changes (drug signature) with disease-associated gene expression (disease signature).

This approach aims to find drugs that can reverse disease-related gene expression patterns. Our Lab is focused on three components of this approach:


Brain Cell type-specific drug perturbations

Development of a comprehensive repository for transcriptomic drug perturbations utilizing human-induced pluripotent stem cell (iPSC)-derived brain cell types.

 The drug-induced transcriptomic responses within the dataset will allow us to leverage brain cell type-specific drug responses against neurodegenerative disease signatures.


Transcriptomic disease signatures

Establishment of neurodegenerative disease signatures by integrating genetics and transcriptomics.


Validation in in vitro disease models

Validation of prioritized drugs in tri-cultures consisting of iPSC-derived neurons, astrocytes, and microglia obtained from patients.